Posted by Dana Blankenhorn @ 5:42 am in its late-stage trial does not end the debate we mentioned a few weeks ago concerning GSMs, amyloid plaques and Alzheimer’s Disease. (Picture from Myriad Genetics.) Myriad Genetics immediately pulled the drug and its stock fell almost $3/share. The company said it will concentrate on genetic testing after presenting its findings in detail later this month. Flurizan aimed to stop development of all amyloid plaques. Gamma-secretase modulators (GSMs) only go after the long ones. The idea is that just as there is good and bad cholesterol, there are good and bad amyloids. Long strings bad, short strings good. By increasing the number of short strings, which also act to prevent development of the long strings, you can keep them from collecting and blocking brain arteries. That’s the theory,...
[read full story]
Your Web Site
